Clinical Trial Update: LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis. [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of STN1013800 (oxymetazoline HCl 0.1% eye drops) for the treatment of acquired blepharoptosis. The trial is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Blepharoptosis

Drugs mentioned

• STN1013800 (oxymetazoline hydrochloride)

Snippet

Sponsor: Santen SAS | Conditions: Acquired Blepharophimosis | Phase 3 | Status: RECRUITING